Table 1. Patient characteristics Patient... | American Society of Hematology

Table 1.

Patient characteristics

Patient	Age, y	Sex	Disease	Transplant	Number of prior regimens for cGVHD	Overall cGVHD severity	Time from transplant to initiation of abatacept, y	Time from GVHD onset to initiation of abatacept, y	Dose level	Doses received
1*	53	F	MDS	NMA; MMUD	6	Severe	4.01	3.94; P	1	5
2	72	M	AML	NMA; MUD	3	Moderate	2.50	2.14; DN	1	6
3*	24	F	ALL	MA; MUD	8	Severe	3.19	2.68; DN	1	18
4	53	F	MM	NMA; MUD	8	Severe	3.75	2.39; DN	2	18
6	53	F	AML	MA ; MUD	5	Moderate	4.02	3.96; Q	2	7
7	62	M	AML	MA; MUD	4	Severe	0.90	0.44; DN	2	4
8*	66	F	AML	NMA; MUD	6	Moderate	1.87	1.43; DN	2	6
9*	65	M	CLL	NMA; MUD	2	Severe	3.61	3.19; DN	2	18
10*	55	F	AML	MA; MUD	1	Moderate	0.92	0.16; DN	2	11
11*	61	F	CML	NMA; MUD	3	Severe	2.24	1.59; DN	2	6
12*	71	M	NHL	NMA; MUD	2	Severe	2.88	1.86; DN	2	18
13	59	M	CLL	NMA; MUD	2	Moderate	4.17	3.48; DN	2	6
14	61	M	AML	MA; MRD	3	Severe	2.41	1.50; DN	2	18
15	39	M	AML	MA; MUD	5	Severe	4.20	1.28; DN	2	6
16	31	M	AML	MA; MUD	7	Severe	9.30	9.77; P	2	6
17	39	F	AML	NMA; MRD	3	Moderate	1.67	1.02; DN	2	11

Patient	Age, y	Sex	Disease	Transplant	Number of prior regimens for cGVHD	Overall cGVHD severity	Time from transplant to initiation of abatacept, y	Time from GVHD onset to initiation of abatacept, y	Dose level	Doses received
1*	53	F	MDS	NMA; MMUD	6	Severe	4.01	3.94; P	1	5
2	72	M	AML	NMA; MUD	3	Moderate	2.50	2.14; DN	1	6
3*	24	F	ALL	MA; MUD	8	Severe	3.19	2.68; DN	1	18
4	53	F	MM	NMA; MUD	8	Severe	3.75	2.39; DN	2	18
6	53	F	AML	MA ; MUD	5	Moderate	4.02	3.96; Q	2	7
7	62	M	AML	MA; MUD	4	Severe	0.90	0.44; DN	2	4
8*	66	F	AML	NMA; MUD	6	Moderate	1.87	1.43; DN	2	6
9*	65	M	CLL	NMA; MUD	2	Severe	3.61	3.19; DN	2	18
10*	55	F	AML	MA; MUD	1	Moderate	0.92	0.16; DN	2	11
11*	61	F	CML	NMA; MUD	3	Severe	2.24	1.59; DN	2	6
12*	71	M	NHL	NMA; MUD	2	Severe	2.88	1.86; DN	2	18
13	59	M	CLL	NMA; MUD	2	Moderate	4.17	3.48; DN	2	6
14	61	M	AML	MA; MRD	3	Severe	2.41	1.50; DN	2	18
15	39	M	AML	MA; MUD	5	Severe	4.20	1.28; DN	2	6
16	31	M	AML	MA; MUD	7	Severe	9.30	9.77; P	2	6
17	39	F	AML	NMA; MRD	3	Moderate	1.67	1.02; DN	2	11

AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; DN, de novo chronic GVHD; F, female; M, male; MA, myeloablative; MDS indicates myelodysplastic syndrome; MMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; NHL, non-Hodgkin lymphoma; NMA, nonmyeloablative; P, progressive from onset of acute GVHD; Q, quiescent from onset of acute GVHD.

Clinical responder.

View Large

This Feature Is Available To Subscribers Only